AI Article Synopsis
- About 15% of schizophrenia patients also experience obsessive-compulsive disorder (OCD) symptoms, prompting a study on the effects of aripiprazole for those with both conditions.
- In a 6-week trial involving 15 adults with schizophrenia and obsessive-compulsive symptoms (OCS), 7 participants completed the study, showing significant improvement in symptoms as measured by various scales.
- The findings indicate that aripiprazole may provide modest benefits for schizophrenia patients with OCS, highlighting the need for further research in this area.
Article Abstract
Background: Approximately 15% of patients with schizophrenia also meet DSM-IV criteria for obsessive-compulsive disorder (OCD) at some point in their illness, a rate considerably higher than in the general population. This study examined aripiprazole treatment of patients with comorbid schizophrenia and obsessive-compulsive symptoms (OCS) that did not meet full criteria for OCD.
Method: Physically healthy adults aged 18 to 65 years with DSM-IV schizophrenia and a minimum score of 16 on the Yale-Brown Obsessive Compulsive Scale (YBOCS) were eligible to participate in this 6-week, open-label, flexible-dose trial of aripiprazole monotherapy. Patients currently taking another antipsychotic medication were concurrently down-titrated from their current antipsychotic and up-titrated with aripiprazole, starting with 15 mg/day. Coadministration of the 2 medications lasted from 7 to 14 days, until a stable therapeutic dose of 10 to 30 mg/day was reached. Subjects were recruited into the study, which was conducted at the Schizophrenia Clinic of Stanford University School of Medicine, between January 2005 and December 2006.
Results: Of 15 eligible patients, 7 completed the trial. All 7 had at least minimal improvement on the YBOCS, the Clinical Global Impressions (CGI) scale, and the Positive and Negative Syndrome Scale (PANSS). At week 6, the mean CGI-Improvement scale score was 2.3 (much improved). Mean PANSS scores decreased from 75 to 56, a mean decrease of 21%, (p < .05). On the YBOCS, 6 of 7 completers showed a change of greater than 35% from baseline to week 6.
Conclusion: These results suggest that aripiprazole monotherapy can modestly improve the outcome for some schizophrenia patients with obsessive-compulsive symptoms. Further studies with aripiprazole under controlled conditions are indicated for this population of patients. Overall, even modest improvement in global functioning due to an improvement in an OCS component may be clinically meaningful for this difficult-to-treat subset of schizophrenia patients.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.4088/jcp.v69n1202 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Evaluating Delta-8-THC-Induced Psychosis: A Systematic Review.
Clin Neuropharmacol
January 2025
Eastern Virginia Medical School, Norfolk, VA.
Objectives: This study reviews literature on the psychiatric effects of delta-8-THC, particularly psychosis and severe mental health outcomes, to highlight the need for further research and regulation.
Background: Marijuana, the most widely used illicit drug in the United States, sees increasing use due to legalization. Although moderate use is generally safe, adverse effects can occur, especially in those with preexisting conditions.
Clinical and Demographic Predictors of Early Clozapine Discontinuation Across Mood and Psychotic Disorders.
J Clin Psychopharmacol
January 2025
Department of Pharmacy, Mayo Clinic, Rochester, MN.
Background: Clozapine is effective for treatment-resistant schizophrenia and bipolar disorder but is often discontinued due to adverse effects. This study compared early clozapine discontinuation rates and reasons in patients with mood and psychotic disorders.
Methods: Data from all individuals with mood or psychotic disorders who initiated clozapine for the first time at the inpatient psychiatric unit of Mayo Clinic, Rochester, Minnesota, between 2014 and 2022 were retrospectively analyzed.
Association between daytime sleepiness and quality of life in outpatients with schizophrenia.
Sleep Biol Rhythms
January 2025
Department of Psychiatry, Nihon University School of Medicine, 30-1 Oyaguchi-Kamicho, Itabashi-Ku, 173-8610 Tokyo, Japan.
This study aimed to investigate the prevalence of daytime sleepiness (DS) and its impact on quality of life (QOL) in outpatients with schizophrenia in the maintenance phase, as well as to identify the factors associated with DS. A total of 191 outpatients with schizophrenia completed a self-administered questionnaire including questions on lifestyle, sleep habits, DS, QOL, and sleep disorders. Insomnia, DS, and QOL were evaluated by the Athens Insomnia Scale (AIS), the Epworth Sleepiness Scale (ESS), and the MOS 8-Item Short-Form Health Survey (SF-8), respectively.
View Article and Find Full Text PDFObjective: Both general medical and mental health services were disrupted during the pandemic. It is unclear how these disruptions played out for people with various mental health diagnoses. We compared change in mental health status and use of mental health services between four psychiatric groups: schizophrenia spectrum disorders, bipolar disorder, unipolar depression, and anxiety/obsessive-compulsive disorder (OCD).
View Article and Find Full Text PDFEarly career psychiatrists' perceptions of and training experience in electroconvulsive therapy: A cross-sectional survey across Europe.
Eur Psychiatry
January 2025
Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.
Background: Electroconvulsive therapy (ECT) is a safe and effective treatment for several major psychiatric conditions, including treatment-resistant depression, mania, and schizophrenia; nevertheless, its use remains controversial. Despite its availability in some European countries, ECT is still rarely used in others. This study aims to investigate the experiences and attitudes of early career psychiatrists (ECPs) across Europe towards ECT and to examine how their exposure to ECT influences their perceptions.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!